GlassScriptPhysician profile
Breanna Walters
NPI 1922668300
$1,715.88
in general payments reported to CMS, 2019-2025
27 companies · $402 in 2025
The $402 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.10 · 2020: $31.01 · 2021: $144 · 2022: $281 · 2023: $400 · 2024: $426 · 2025: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,228.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $365.31 | 2020-2025 | |
| Corium, LLC | $206.79 | 2022-2023 | Azstarys |
| Novo Nordisk INC | $167.59 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $107.11 | 2022-2025 | Repatha, Otezla, Otezla |
| Almatica Pharma LLC | $79.58 | 2022-2023 | Loreev Xr, Gralise, Sertraline Hcl |
| Glaxosmithkline, LLC. | $79.21 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbvie INC. | $72.13 | 2025 | |
| Seqirus USA INC | $66.10 | 2025 | Flucelvax, Fluad |
| Astrazeneca Pharmaceuticals LP | $63.63 | 2021-2025 | Airsupra |
| Lilly USA, LLC | $61.45 | 2023-2025 | Mounjaro, Kisunla, Trulicity |
| Sanofi Pasteur INC. | $54.79 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $50.60 | 2023-2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.04 | 2023-2025 | Xifaxan |
| Sumitomo Pharma America, INC. | $37.57 | 2023-2024 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.10 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $27.67 | 2023-2024 | Aptima |
| Novartis Pharmaceuticals Corporation | $23.98 | 2022 | |
| Ironshore Pharmaceuticals INC. | $23.43 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.58 | 2023 | |
| Linus Health, INC. | $19.75 | 2023 | |
| Global Blood Therapeutics, INC. | $19.56 | 2021 | |
| Corcept Therapeutics | $18.97 | 2024 | Korlym |
| Exact Sciences Corporation | $18.23 | 2024 | Cologuard Collection Kit |
| Vertex Pharmaceuticals Incorporated | $17.85 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.38 | 2022 | |
| Ardelyx, INC. | $15.64 | 2024 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $12.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Breanna Walters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.